UVT
BiologicalChemically-treated, viro-inactivated, freeze-dried and irradiated umbilical vein allograft placed in replacement of a failed synthetic sling during a surgical act performed by the investigator.
NCT Number: NCT05207189
The purpose of this open, multi center trial is to evaluate a new biological replacement for synthetic slings in the treatment of female stress urinary incontinence.
Looking for future studies?
Notify Me40 year–75 year
Female
Interventional
Phase 2
Hôtel-Dieu, CHU de Nantes, Nantes, France
It was estimated that more than 9 million French people are affected by urinary incontinence, of which 1% are treated surgically. Indeed, if medical treatment or rehabilitation fails, surgical treatment must be considered. Sling implantation is a commonly used surgical technique to treat stress urinary incontinence as it allows for a reduction in surgery time and morbidity and can be placed under local anesthesia. However, the risk of complications associated with the use of synthetic products is high and contributes to the recent decline of popularity of synthetic slings. As the demand for incontinence treatment remains high, fascia autograft surgeries are being proposed, even though they require an additional surgical procedure and expose the patient to complications at the donor site of the graft.
The study product aims to address the growing need for a safer but equally effective implant to avoid autografting while keeping the standard surgical technique.
The aim of this exploratory study is to evaluate a biological sling replacement to failed synthetic slings in the treatment of female stress urinary incontinence.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical vein allograft placed in replacement of a failed synthetic sling during a surgical act performed by the investigator.
Time frame: 6 months
Use of less than 2 pads a day
Time frame: 6 months
Evaluation of urinary retention, dysuria, local inflammation, irritation of suture and suspension areas, and other indirect symptoms
Time frame: 15 days, 6 weeks, 3 months, 6 months, 12 months
Monitoring of urinary retention, dysuria, local inflammation, irritation of suture and suspension areas, and other indirect symptoms
Time frame: 15 days, 6 weeks, 3 months, 6 months, 12 months
Pain evaluated from 0: no pain to 10: worst imaginable pain on visual analog scale (VAS)
Time frame: 15 days, 6 weeks, 3 months, 6 months, 12 months
Continence evaluated by uroflow test and 3-day voiding diary
Time frame: 6 weeks, 3 months, 6 months, 12 months
Decrease in the score of the International Consultation on Incontinence Questionnaire - Urinary Incontinence - Short Form (ICIQ-UI-SF) (0 = no UI, 21 = very severe UI)
Time frame: 6 weeks, 3 months, 6 months, 12 months
Decrease of the Urogenital Distress Inventory (UDI-6) score (0 = no distress caused by UI symptoms, 100 = highest possible distress cause by UI symptoms)
Time frame: 6 weeks, 3 months, 6 months, 12 months
Decrease of the Incontinence Impact Questionnaire (IIQ-7) score (0 = no impact of UI on health-related quality of life, 100 = highest possible impact of UI on health-related quality of life)
TBF Genie Tissulaire
Industry
Phase II Study Evaluating the Treatment of Women Urinary Incontinence by Suburethral Slings; UVT Allograft; in Patients Presenting With Complication of the Synthetic Sling Treatment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03727945
Female Stress Incontinence, Female Urogenital Diseases
View Trial DetailsNCT03996070
Female Stress Incontinence
Basingstoke, Hampshire, United Kingdom
View Trial DetailsNCT03174431
Female Stress Incontinence
Chapel Hill, North Carolina, United States
View Trial DetailsNCT03682926
Female Stress Incontinence
View Trial Details